New! You can now keep track of new articles from Annals of Oncology on your personalized homepage!
Background: Oxaliplatin (OXA) and irinotecan (IRI) are active drugs in first-line as well as second-line treatment of advanced colorectal cancer patients, their toxicity profiles are not overlapping, and both drugs have shown synergism with folinic acid-modulated 5-fluorouracil (5-FU). We planned...
Background: A phase II study was conducted to assess the efficacy and tolerability of combination therapy with capecitabine and cisplatin in patients with advanced gastric cancer. Patients and methods: Patients with previously untreated metastatic or unresectable measurable gastric adenocarcinoma...